Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.

ABSTRACT:

Aim

To assess the efficacy and safety of weekly docetaxel plus a fixed-dose rate (FDR) of gemcitabine in metastatic esophageal squamous cell carcinoma (SCC).

Methods

A multi-center, open-label, prospective phase II study was designed. Thirty-three esophageal SCC patients with documented progression after fluoropyrimidine/platinum-based first-line chemotherapy were enrolled and treated with docetaxel 35 mg/m(2) and gemcitabine 1000 mg/m(2) iv at a FDR (10 mg/m(2) per minute) on days 1 and 8. Treatment was repeated every twenty-one days until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was response rate (RR), and secondary endpoints were safety, progression-free survival (PFS) and overall survival (OS).

Results

Combination of

SUBMITTER: Lee MY 

PROVIDER: S-EPMC4394089 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature